When Will Retatrutide Be FDA Approved? Timeline, Trials & Projections (2026)

What Is Retatrutide's Current FDA Status? (Quick Answer)

Retatrutide (LY3437943) is investigational. Eli Lilly has not filed a New Drug Application with the FDA as of May 2026. Phase 3 TRIUMPH trials are ongoing, with the first read-out (TRIUMPH-4) reporting in December 2025. Based on the remaining trial schedule plus the FDA's standard 12-month review, the most defensible approval window is late 2027 to 2028. This is an analyst-estimated range, not a Lilly-confirmed date.

Why No BLA Has Been Filed Yet

A BLA cannot be filed until Phase 3 is complete. The pivotal obesity trials Lilly needs for a commercial label, TRIUMPH-1 and TRIUMPH-3, reached primary completion in April 2026 (ClinicalTrials.gov). Only after the data is locked, cleaned, and assembled into the regulatory package does the BLA get submitted. The FDA then runs a standard review of about 12 months from submission under PDUFA, or about 8 months under priority review if granted (for a new molecular entity, the 10- or 6-month review goal starts after a 60-day filing period). That sequence is why a 2026 approval, which some less-careful coverage still suggests, does not match the underlying schedule.

The TRIUMPH Phase 3 Program: What Has Happened, What Is Next

The TRIUMPH program is the cluster of Phase 3 trials that has to clear before retatrutide can reach the FDA. The four core trials cover different populations: general obesity, obesity with established cardiovascular disease, obesity with knee osteoarthritis, and a long-running cardiovascular outcomes study. Only TRIUMPH-4 has reported a primary result so far.

The four core TRIUMPH trials. TRIUMPH-4 (knee OA + obesity) reported in December 2025; the rest read out across 2026.

TRIUMPH-4 Results (December 2025): The First Phase 3 Data

TRIUMPH-4 was the first Phase 3 trial to read out and the first concrete look at retatrutide's efficacy outside the Phase 2 cohort. The trial enrolled adults with obesity and knee osteoarthritis and ran for 68 weeks. On the 12mg maintenance dose, participants lost an average of 28.7% of body weight versus 2.1% on placebo, as reported by Eli Lilly in December 2025 (peer-reviewed publication pending). That figure exceeds the Phase 2 result of 24.2% at 48 weeks, which was already among the largest body-weight reductions reported in a randomized obesity trial.

The likely reason for the bigger number is simple: more time on drug. A 68-week treatment window gives the dose more room to work. The trial also reported secondary improvements in knee-pain scores, which matters for the eventual label scope but does not change the regulatory math for an obesity indication. Bear in mind: TRIUMPH-4 enrolled obesity plus knee OA, so the population is not identical to the general obesity cohort. The bigger label-defining numbers will come from TRIUMPH-1 later in 2026.

Note on Phase 3 Doses Versus Phase 2

The Phase 3 TRIUMPH-4 design used three maintenance doses: 4mg, 9mg, and 12mg. That is a different set than the Phase 2 randomized arms of 1mg, 4mg, 8mg, and 12mg. The 9mg dose is new to Phase 3 and was introduced after Phase 2 dose-response data informed the choice. If you read older coverage that lists "1mg, 4mg, 8mg, 12mg" as the Phase 3 doses, that is the Phase 2 schedule, not the current pivotal trial.

What the Remaining 2026 Readouts Mean for the Timeline

The trials that drive the commercial obesity label are TRIUMPH-1 (general obesity) and TRIUMPH-3 (obesity plus cardiovascular disease). TRIUMPH-1 reported in May 2026 and TRIUMPH-3 (with TRIUMPH-2) in July 2026, so the Phase 3 results behind a filing are now in. Industry reporting from Clinical Trials Arena in December 2025 flagged seven additional Phase 3 readouts expected during 2026, which was consistent with a Q4 2026 or Q1 2027 submission target. Lilly has since said it plans to submit a Biologics License Application (BLA) in the first quarter of 2027, after completing its chemistry, manufacturing and controls package. Any safety signal or amended analysis would widen the timeline.

Realistic Retatrutide FDA Timeline: 2027 to 2028

A defensible projected timeline has four moving pieces: Phase 3 completion, the BLA submission, the FDA review period, and the commercial launch ramp. Each one carries its own range of uncertainty. The table below stitches them together using published analyst estimates from GoodRx, Drugs.com, and beyondstemcells.com, plus the trial completion dates on ClinicalTrials.gov.

Factors That Could Speed Up or Slow Down Approval

A few specific things would shift the window. Priority review, if the FDA granted it, would trim roughly four months (about 8 months from submission instead of 12). Breakthrough Therapy designation is a separate program and does not by itself grant priority review. A clean safety profile across TRIUMPH-1 and TRIUMPH-3 would help Lilly file faster and would discourage the FDA from requesting additional studies. Cardiovascular outcomes data from TRIUMPH-Outcomes is long-term and would not gate the initial obesity approval, though it would shape any later cardiovascular indication. On the slower side: any safety signal in late readouts, FDA requests for additional analyses, or manufacturing-scale issues at the levels needed for a major obesity launch.

How This Compares to Tirzepatide's Approval Timeline

Tirzepatide is the closest precedent Lilly has run. Phase 3 SURPASS trials began in 2019. Lilly submitted the diabetes NDA in September 2021 (the FDA approval letter cites an application dated September 14, 2021), and the FDA approved Mounjaro on May 13, 2022. The obesity approval (Zepbound) followed in November 2023. From Phase 3 start to final obesity approval was roughly four years, and from NDA submission to first approval was about eight months under priority review (for a new molecular entity, the six-month review goal starts after a 60-day filing period). Retatrutide's Phase 3 program started in 2023 (TRIUMPH-3 in May 2023, per ClinicalTrials.gov), so a 2027 to 2028 obesity approval lines up cleanly with the same four-year arc. The caveat is that no two drugs travel identical regulatory paths; safety questions, manufacturing readiness, and FDA priorities are all variables that move independently.

Comparative weight-loss data across retatrutide Phase 2, TRIUMPH-4 Phase 3, and tirzepatide SURMOUNT-1. Cross-trial comparisons are directional, not equivalent.

Related video

Can You Get Retatrutide Right Now? Legitimate Access Only

There are two lawful routes to retatrutide while the FDA timeline plays out: a clinical trial and, for a narrow group of patients, Lilly's physician-requested expanded access program. Compounded retatrutide is not lawful, and research peptides are a source this page does not endorse. For a more complete breakdown of access logistics by country and by route, see our retatrutide availability by country guide and the how to get retatrutide today walkthrough.

Option 1: Enroll in a TRIUMPH Clinical Trial

A TRIUMPH trial site provides pharmaceutical-grade retatrutide at no cost, with medical oversight and structured follow-up. Eligibility usually requires age 18 or older, a BMI of 30 or higher (or 27 or higher with a documented comorbidity), and no current GLP-1 medication. Each trial layers on its own inclusion criteria; TRIUMPH-3 needs established cardiovascular disease, TRIUMPH-4 needed obesity plus knee osteoarthritis, and so on. ClinicalTrials.gov is the canonical search index (filter for "retatrutide" and Phase 3), and Lilly's trial portal at trials.lilly.com is the company-run portal. Slots fill quickly, and not every site is recruiting at any given moment.

Option 2: Lilly's Expanded Access Program (Narrow, Physician-Requested)

Lilly runs an expanded access program for retatrutide before FDA approval, "for a limited number of patients who meet specific medical criteria and cannot enroll in a clinical trial" (Reuters via KSL). Patients must be 18 or older with a BMI of 35 or more despite tolerating the highest available dose of weight-management therapy, have two or more serious or life-threatening obesity-related complications, be unable to join an ongoing retatrutide (or comparable) trial, and have discussed all standard treatment options, including bariatric surgery, with their doctor (Lilly Medical; ClinicalTrials.gov NCT07629401). The treating physician applies to the FDA as the sponsor of a patient-specific investigational new drug (IND) application and must obtain institutional review board (IRB) approval. Lilly provides the drug at no cost, and direct-to-patient shipping is not available. It is not something a patient can buy.

Why Compounded Retatrutide Is Not an Option

The FDA states: "Retatrutide and cagrilintide cannot be used in compounding under federal law." Compounding pharmacies (503A or 503B) cannot lawfully supply it, and a prescription does not change that. The FDA has warned telehealth companies for marketing retatrutide, API distributors for selling it to compounders, and outsourcing facilities for repackaging it. Our compounded retatrutide guide explains the details. If you see compounded retatrutide offered, treat the offer itself as a red flag.

A Note on Grey-Market "Research Peptides"

Some vendors sell retatrutide as a "research peptide" outside any regulated supply chain. These products are not intended for human use, are not subject to FDA oversight, and have variable purity and labeling accuracy. GLP3Planner does not link to or recommend research peptide vendors. This article exists to track the regulatory timeline, not to route readers to unregulated sources.

What Changes Once Retatrutide Is Approved

FDA approval would shift retatrutide from investigational to standard prescription. Eli Lilly will assign a brand name (the tirzepatide playbook used Mounjaro for diabetes and Zepbound for obesity, so a parallel split is plausible). Insurance coverage decisions follow Lilly's pricing and payer contracting, and prior authorization rules will probably mirror those for Wegovy and Zepbound. Compounding is not a lawful lane today: the FDA states retatrutide cannot be used in compounding under federal law.

References

1. ClinicalTrials.gov. A Study of Retatrutide (LY3437943) in Adults With Obesity (TRIUMPH-1). NCT05929066. Accessed May 2026. clinicaltrials.gov/study/NCT05929066. (Master Phase 3 obesity protocol; canonical entry for the trial's design, expected completion, and primary endpoint.)
2. ClinicalTrials.gov. A Study of Retatrutide (LY3437943) in Adults With Obesity and Established Cardiovascular Disease (TRIUMPH-3). NCT05882045. Accessed May 2026. clinicaltrials.gov/study/NCT05882045. (Phase 3 arm covering obesity with established cardiovascular disease; one of the label-defining trials for any cardiometabolic claim.)
3. ClinicalTrials.gov. A Study of Retatrutide (LY3437943) in Adults With Obesity and Knee Osteoarthritis (TRIUMPH-4). NCT05931367. Accessed May 2026. clinicaltrials.gov/study/NCT05931367. (Primary completion November 2025, 68-week treatment period, 4mg/9mg/12mg dose arms; source for the 28.7% body weight loss figure.)
4. ClinicalTrials.gov. A Study of Retatrutide (LY3437943) to Assess Cardiovascular Outcomes (TRIUMPH-Outcomes). NCT06383390. Accessed May 2026. clinicaltrials.gov/study/NCT06383390. (Long-term cardiovascular outcomes trial that does not gate initial obesity approval but informs any later cardiovascular indication.)
5. Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972. nejm.org/doi/full/10.1056/NEJMoa2301972. (Phase 2 anchor trial: 24.2% body weight loss at 48 weeks on 12mg, n=338, dose-response across 1mg/4mg/8mg/12mg arms.)
6. Eli Lilly and Company. What to know about retatrutide. lilly.com. Accessed May 2026. lilly.com/news/stories/what-to-know-about-retatrutide. (Official Lilly statement on investigational status and the company's framing of the TRIUMPH program.)
7. GoodRx. Retatrutide for Weight Loss: Availability, Dosage, and More. Accessed May 2026. goodrx.com (retatrutide for weight loss). (Cited as one of the analyst sources for the 2026 or 2027 approval estimate referenced across the SERP.)
8. Clinical Trials Arena. Eli Lilly's retatrutide hits primary endpoint in Phase III TRIUMPH-4 obesity and knee osteoarthritis trial. December 2025. Accessed May 2026. clinicaltrialsarena.com (retatrutide TRIUMPH-4). (Industry coverage of Eli Lilly's December 2025 TRIUMPH-4 topline announcement, including the 28.7% body weight loss figure on 12mg, the 2.1% placebo figure, and the schedule for remaining 2026 readouts.)
9. Eli Lilly and Company. Lilly's retatrutide demonstrated significant weight loss in adults with obesity and knee osteoarthritis (TRIUMPH-4 topline results). Investor news release. December 2025. Accessed May 2026. investor.lilly.com/news-releases. (Primary corporate readout for the TRIUMPH-4 efficacy and safety summary; the source for the 28.7% versus 2.1% figures cited throughout this article. Full peer-reviewed publication is pending.)
10. U.S. Food and Drug Administration. FDA approves novel, dual-targeted treatment for type 2 diabetes (Mounjaro / tirzepatide). May 13, 2022. Original URL now returns 404; FDA links this archive copy from its Novel Drug Approvals for 2022 page. Accessed October 2, 2026. fda.gov press release (FDA archive copy). (Confirms the May 13, 2022 Mounjaro approval date used to anchor the tirzepatide precedent comparison.)